JPWO2022076830A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022076830A5 JPWO2022076830A5 JP2023521484A JP2023521484A JPWO2022076830A5 JP WO2022076830 A5 JPWO2022076830 A5 JP WO2022076830A5 JP 2023521484 A JP2023521484 A JP 2023521484A JP 2023521484 A JP2023521484 A JP 2023521484A JP WO2022076830 A5 JPWO2022076830 A5 JP WO2022076830A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- composition
- polynucleotide
- type
- donor polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091033319 polynucleotide Proteins 0.000 claims 35
- 102000040430 polynucleotide Human genes 0.000 claims 35
- 239000002157 polynucleotide Substances 0.000 claims 35
- 210000004027 cell Anatomy 0.000 claims 33
- 108090000623 proteins and genes Proteins 0.000 claims 25
- 239000000203 mixture Substances 0.000 claims 22
- 102000004169 proteins and genes Human genes 0.000 claims 21
- 238000000034 method Methods 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 8
- 108091033409 CRISPR Proteins 0.000 claims 5
- 238000010354 CRISPR gene editing Methods 0.000 claims 5
- 102000008579 Transposases Human genes 0.000 claims 5
- 108010020764 Transposases Proteins 0.000 claims 5
- 230000000536 complexating effect Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 108020004485 Nonsense Codon Proteins 0.000 claims 2
- 108700026244 Open Reading Frames Proteins 0.000 claims 2
- 102000004389 Ribonucleoproteins Human genes 0.000 claims 2
- 108010081734 Ribonucleoproteins Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 1
- 102000008300 Mutant Proteins Human genes 0.000 claims 1
- 108010021466 Mutant Proteins Proteins 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 238000012937 correction Methods 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089220P | 2020-10-08 | 2020-10-08 | |
| US63/089,220 | 2020-10-08 | ||
| PCT/US2021/054190 WO2022076830A1 (en) | 2020-10-08 | 2021-10-08 | Type i crispr-associated transposase systems |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023544822A JP2023544822A (ja) | 2023-10-25 |
| JP2023544822A5 JP2023544822A5 (https=) | 2024-10-16 |
| JPWO2022076830A5 true JPWO2022076830A5 (https=) | 2024-10-16 |
Family
ID=81126112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521484A Pending JP2023544822A (ja) | 2020-10-08 | 2021-10-08 | Ｉ型ｃｒｉｓｐｒ関連トランスポザーゼシステム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230383315A1 (https=) |
| EP (1) | EP4204562A4 (https=) |
| JP (1) | JP2023544822A (https=) |
| CN (1) | CN116234918A (https=) |
| AU (1) | AU2021356560A1 (https=) |
| CA (1) | CA3194645A1 (https=) |
| WO (1) | WO2022076830A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117363554B (zh) * | 2023-12-08 | 2024-04-09 | 清华大学 | 一种工程改造的嗜盐微生物及其构建方法和应用 |
| CN118909782B (zh) * | 2024-10-10 | 2025-02-18 | 中国科学院烟台海岸带研究所 | 一种除异味净水藻及其净化应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3124110A1 (en) * | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
| CA3132197A1 (en) * | 2019-03-07 | 2020-09-10 | The Trustees Of Columbia University In The City Of New York | Rna-guided dna integration using tn7-like transposons |
-
2021
- 2021-10-08 CA CA3194645A patent/CA3194645A1/en active Pending
- 2021-10-08 JP JP2023521484A patent/JP2023544822A/ja active Pending
- 2021-10-08 WO PCT/US2021/054190 patent/WO2022076830A1/en not_active Ceased
- 2021-10-08 US US18/248,252 patent/US20230383315A1/en active Pending
- 2021-10-08 AU AU2021356560A patent/AU2021356560A1/en not_active Abandoned
- 2021-10-08 EP EP21878622.6A patent/EP4204562A4/en not_active Withdrawn
- 2021-10-08 CN CN202180072877.XA patent/CN116234918A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pellagatti et al. | Application of CRISPR/Cas9 genome editing to the study and treatment of disease | |
| Zhu | Advances in CRISPR/cas9 | |
| Ain et al. | Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN | |
| Würtele et al. | Illegitimate DNA integration in mammalian cells | |
| Woo et al. | DNA-free genome editing in plants with preassembled CRISPR-Cas9 ribonucleoproteins | |
| ES2796087T3 (es) | Métodos y composiciones para el tratamiento de beta talasemia | |
| EP3559230B1 (en) | Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome | |
| Sukegawa et al. | Plant genome editing: ever more precise and wide reaching | |
| Ma et al. | CRISPR/Cas9-mediated gene manipulation to create single-amino-acid-substituted and floxed mice with a cloning-free method | |
| JP2021505159A5 (https=) | ||
| EP3536796A1 (en) | Gene knockout method | |
| Sertori et al. | Genome editing in zebrafish: a practical overview | |
| JPWO2019217943A5 (https=) | ||
| CN113366106A (zh) | 用于递送转基因的组合物和方法 | |
| JP6958917B2 (ja) | 遺伝子ノックイン細胞の作製方法 | |
| Huang et al. | CRISPR editing in biological and biomedical investigation | |
| CN114981445B (zh) | 修饰的双链供体模板 | |
| Zhang et al. | Crispr/Cas9‐mediated cleavages facilitate homologous recombination during genetic engineering of a large chromosomal region | |
| Kues et al. | Applications of genome editing tools in stem cells towards regenerative medicine: An update | |
| Sadr et al. | CRISPR-Cas9 as a potential cancer therapy agent: An update | |
| Yuan et al. | Epigenome editing based treatment: Progresses and challenges | |
| EP3562944B1 (en) | Transgenic rabbits and method for bioproduction | |
| Hong et al. | Mitochondrial DNA editing: Key to the treatment of neurodegenerative diseases | |
| Schmouth et al. | Modelling human regulatory variation in mouse: finding the function in genome-wide association studies and whole-genome sequencing | |
| Aliciaslan et al. | Prime editing: the next frontier in precision gene therapy |